All Japanese osteoarthritis deal could total 12 billion yen

4 September 2017

Ono Pharmaceutical (TYO: 4528) and Seikagaku Corp (TYO: 4548) have announced a deal for a co-development and marketing collaboration on an osteoarthritis candidate in Japan that could be worth 12 billion yen ($110 million).

Under the agreement, Ono acquires co-development and exclusive marketing rights related to SI-613 in Japan, with Seikagaku receiving an upfront payment of 2 billion yen and milestone payments up to a maximum total amount of 10 billion yen over multiple years upon future progress in development and marketing.

SI-613, a formulation in which hyaluronic acid and a non-steroidal anti-inflammatory drug are chemically bound using Seikagaku’s proprietary technology, is currently under Phase III clinical development in Japan for the treatment of osteoarthritis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK